Psychostimulants in moderate to severe affective disorder: A systematic review of randomized controlled trials

References

• Investigating in mental health. World Health Organization 2003; 3–48.
   Google Scholar
• Connoly KR and Thase ME. If at first you don't succeed: A review of the evidence for antidepressant augmentation, combination and switching strategies. Drugs 2011;71:43–64.
   PubMedGoogle Scholar
• Tranter R, O’Donovan C, Chandarana P, Kennedy S. Prevalence and outcome of partial remission in depression. J Psychiatry Neurosci 2002;27:241–7.
   PubMed Web of Science ®Google Scholar
• Fava M. Pharmacological approaches to the treatment of residual symptoms. J Psychopharmacol 2006;20:29–34.
   PubMed Web of Science ®Google Scholar
• Judd LL, Akiskal HS, Maser JD, Zeller PJ, Endicott J, Coryell W, et al. Major depressive disorder: A prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Dis 1998;50:97–108.
   PubMed Web of Science ®Google Scholar
• Zajecka JM. Clinical issues in long-term treatment with antidepressants. J Clin Psychiatry 2000;61 Suppl 2:20–5.
   PubMedGoogle Scholar
• Papakostas GI. Managing partial response or nonresponse: Switching, augmentation, and combination strategies for major depressive disorder. J Clin Psychiatry 2009;70:16–25.
   PubMed Web of Science ®Google Scholar
• Linet LS. Treatment of a refractory depression with a combination of fluoxetine and d-amphetamine. Am J Psychiatry 1989;146:803–4.
   PubMedGoogle Scholar
• Stoll AL, Pillay SS, Diamond L, Workum SB, Cole JO. Methylphenidate augmentation of serotonin selective reuptake inhibitors: A case series. J Clin Psychiatry 1996;57:72–6.
   PubMedGoogle Scholar
• Feighner JP, Herbstein J, Damloujii N. Combined MAOI, TCA and direct stimulant therapy of treatment-resistant depression. J Clin Psychiatry 1985;46:206–9.
   PubMed Web of Science ®Google Scholar
• Fawcett J, Kravitz HM, Zajeca JM, Schaff MR. CNS stimulant potentiation of monoamine oxidase inhibitors in treatment-refractory depression. J Clin Psychopharmacol 1991;11:127–32.
   PubMed Web of Science ®Google Scholar
• Lavretsky H, Kumar A. Methylphenidate augmentation of citalopram in elderly depressed patients. Am J Geriatr Psychiatry 2001;9:298–303.
   PubMedGoogle Scholar
• Masand PS, Anand VS, Tanquary JF. Psychostimulant augmentation of second generation antidepressants: A case series. Depress Anxiety 1998;7:89–91.
   PubMed Web of Science ®Google Scholar
• Menza MA, Kaufman KR, Castellanos A. Modafinil augmentation of antidepressant treatment in depression. J Clin Psychiatry 2000;61:378–81.
   PubMed Web of Science ®Google Scholar
• Konuk N, Atasoy N, Atik L, Akay O. Open-label study of adjunct modafinil for the treatment of patients with fatigue, sleepiness, and major depression treated with selective serotonin reuptake inhibitors. Adv Ther 2006;23:646–54.
   PubMed Web of Science ®Google Scholar
• Rasmussen NA, Schrøder P, Olsen LR, Brødsgaard M, Undén M, Bech P. Modafinil augmentation in depressed patients with partial response to antidepressants: A pilot study on self-reported symptoms covered by the major depression inventory (MDI) and the symptom checklist (SCL-92). Nord J Psychiatry 2005;59:173–8.
   PubMed Web of Science ®Google Scholar
• Orr K and Taylor D. Psychostimulants in the treatment of depression: A review of the evidence. CNS Drugs 2007;21:239–57.
   PubMed Web of Science ®Google Scholar
• DeBattista C and Lembke A. Update on augmentation of antidepressant response in resistant depression. Curr Psychiatry Rep 2005;7:435–40.
   PubMedGoogle Scholar
• Wallace LJ. Effects of amphetamine on subcellular distribution of dopamine and DOPAC. Synapse2012 [Epub ahead of print].
   Google Scholar
• Berridge CW and Devilbiss DM. Psychostimulants as cognitive enhancers: The prefrontal cortex, catecholamines, and attention- deficit/hyperactivity disorder. Biol Psychiatry 2011;69:e101–e111.
   PubMed Web of Science ®Google Scholar
• Markowitz JS and Patrick KS. Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder. Clin Pharmacokinet 2001;40:753–72.
   PubMed Web of Science ®Google Scholar
• Etwel FA, Rieder MJ, Bend JR, Koren G. A surveillance method for the early identification of idiosyncratic adverse drug reactions. Drug Safety 2008;31:169–80.
   PubMed Web of Science ®Google Scholar
• Minzenberg MJ and Carter CS. Modafinil: A review of neurochemical actions and effects on cognition. Neuropsychopharmacology 2008;33:1477–502.
   PubMed Web of Science ®Google Scholar
• Kumar R. Approved and investigational uses of modafinil: An evidence-based review. Drugs 2008;68:1803–39.
   PubMed Web of Science ®Google Scholar
• DeBattista C, Doghramji K, Menza MA, Rosenthal MH, Fieve RR. Adjunct modafinil for the short-term treatment of fatigue and s leepiness in patients with major depressive disorder: A preliminary double-blind, placebo-controlled study. J Clin Psychiatry 2003;64:1057–64.
   PubMed Web of Science ®Google Scholar
• Dunlop BW, Crits-Christoph P, Evans DL, Hirschowitz J, Solvason HB, Rickels K, et al. Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness: A double-blind, placebo-controlled study. J Clin Psychopharmacol 2007;27:614–19.
   PubMed Web of Science ®Google Scholar
• Fava M, Thase ME, DeBattista C. A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. J Clin Psychiatry 2005;66:85–93.
   PubMed Web of Science ®Google Scholar
• Abolfazli R, Hosseini M, Ghanizadeh A, Ghaleiha A, Tabrizi M, Raznahan M, et al. Double-blind randomized parallel-group clinical trial of efficacy of the combination fluoxetine plus modafinil versus fluoxetine plus placebo in the treatment of major depression. Depress Anxiety 2011;28:297–302.
   PubMed Web of Science ®Google Scholar
• Beck J, Hemmeter U, Brand S, Muheim F, Hatzinger M, Holsboer-Trachsler E. Modafinil reduces microsleep during partial sleep deprivation in depressed patients. J Psychiatr Res. 2010;44:853–64.
   PubMed Web of Science ®Google Scholar
• Vaishnavi S, Gadde K, Alamy S, Zhang W, Connor K, Davidson JRT. Modafinil for atypical depression: Effects of open-label and double-blind discontinuation treatment. J Clin Psychopharmacol 2006;26:373–8.
   PubMedGoogle Scholar
• Patkar AA, Masand PS, Pae C, Peindl K, Hooper-Wood C, Mannelli P, et al. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression. J Clin Psychopharmacol 2006;26:653–6.
   PubMed Web of Science ®Google Scholar
• Ravindran AV, Kennedy SH, O’Donovan MC, Fallu A, Camacho F, Binder CE. Osmotic-relase oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: Results of a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry 2008;69:87–94.
   PubMed Web of Science ®Google Scholar
• Postolache TT, Rosenthal RN, Hellerstein DJ, Aromin R, Kelton GM, Muran JC, et al. Early augmentation of sertraline with methylphenidate. J Clin Psychiatry 1999;2:123–4.
   Google Scholar
• Little KY. d-Amphetamine versus methylphenidate effects in depressed inpatients. J Clin Psychiatry 1993;54:349–55.
   PubMedGoogle Scholar
• Hare EH, Dominian J, Sharpe L. Phenelzine and dexamphetamine in depressive illness: A comparative trial. Br Med J 1962;1:9–12.
   PubMedGoogle Scholar
• Hare EH, McCance C, McCormick WO. Imipramine and “Drinamyl” in depressive illness: A comparative trial. Br Med J 1964;1:818–20.
   PubMedGoogle Scholar
• Cookson J, Silverstone T. The effects of methylamphetamine on mood and appetite in depressed patients: A placebo-controlled study. Int Clin Psychopharmacol 1986;1:127–33.
   PubMed Web of Science ®Google Scholar
• Elizur A, Wintner I, Davidson S. The clinical and psychological effects of pemoline in depressed patients—A controlled study. Int Pharmacopsychiatry 1979;14:127–34.
   PubMedGoogle Scholar
• Frye MA, Grunze H, Suppes T, McElroy SL, Keck PE, Walden J, et al. A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am J Psychiatry 2007;164:1242–9.
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Ketter TA, Youakim JM, Tiller JM, Yang R, Frye MA. Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: A randomized, multicenter, double-blind, placebo-controlled, proof-of-concept study. J Clin Psychiatry 2010;71:1363–70.
   PubMed Web of Science ®Google Scholar
• Silberman EK, Reus VI, Jimerson DC, Lynott AM, Post RM. Heterogeneity of amphetamine response in depressed patients. Am J Psychiatry 1981;10:1302–7.
   Google Scholar
• Reus VI, Silberman EK, Post RM, Weingartner H. d-Amphetamine: Effects on memory in a depressed population. Biol Psychiatry 1979;14:345–56.
   PubMed Web of Science ®Google Scholar
• ADHD: Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents.Pediatrics 2011;128:1007–22.
   PubMedGoogle Scholar
• Sills TL, Greenshaw AJ, Baker GB, Fletcher PJ. Subchronic fluoxetine treatment induces a transient potentiation of amphetamine-induced hyperlocomotion: Possible pharmacokinetic interaction. Behav Pharmacol 2000;11:109–16.
   PubMedGoogle Scholar
• Sills TL, Greenshaw AJ, Baker GB, Fletcher PJ. Acute fluoxetine treatment potentiates amphetamine hyperactivity and amphetamine-induced nucleus accumbens dopamine release: Possible pharmacokinetic interaction. Psychopharmacology 1999;141:421–7.
   PubMedGoogle Scholar
• Sills TL, Greenshaw AJ, Baker GB, Fletcher PJ. The potentiating effect of sertraline and fluoxetine on amphetamine-induced locomotor activity is not mediated by serotonin. Psychopharmacology 1999;143:426–32.
   PubMedGoogle Scholar
• Ferraro L, Fuxe K, Agnati L, Tanganelli S, Tomasini MC, Antonelli T. Modafinil enhances the increase of extracellular serotonin levels induced by the antidepressant drugs fluoxetine and imipramine: A dual probe microdialysis study in awake rat. Synapse 2005;55:230–41.
   PubMed Web of Science ®Google Scholar
• Ramaswamy S, Mattai A, Wilson DR. Modafinil: Not just for sleep disorders?. Curr Psychiatry 2007;6:67–79.
   Google Scholar
• Videbech P. Modafinil in the treatment of depression: A systematic review. Ugeskr Laeger 2012;174:348–51.
   PubMedGoogle Scholar
• Lam JY, Freeman MK, Cates ME. Modafinil augmentation for residual symptoms of fatigue in patients with a partial response to antidepressants. Ann Pharmacother 2007;41:1005–12.
   PubMed Web of Science ®Google Scholar
• Ninan PT, Hassman HA, Glass SJ, McManus FC. Adjunctive modafinil at initiation of treatment with a selective serotonin reuptake inhibitor enhances the degree and onset of therapeutic effects in patients with major depressive disorder and fatigue. J Clin Psychiatry 2004;65:414–20.
   PubMed Web of Science ®Google Scholar
• DeBattista C, Lembke A, Solvason HB, Ghebremichael R, Poirier J. A prospective trial of modafinil as an adjunctive treatment of major depression. J Clin Psychopharmacol 2004;24:87–90.
   PubMed Web of Science ®Google Scholar
• Markovitz PJ and Wagner S. An open-label trial of modafinil augmentation in patients with partial response to antidepressant therapy. J Clin Psychopharmacol 2003;23:207–9.
   PubMed Web of Science ®Google Scholar
• Price CS and Taylor FB. A retrospective chart review of the effects of modafinil on depression as monotherapy and as adjunctive therapy. Depress Anxiety 2005;21:149–53.
   PubMedGoogle Scholar
• Kaufman KR, Menza MA, Fitzsimmons A. Modafinil monotherapy in depression. Eur Psychiatry 2002;17:167–9.
   PubMedGoogle Scholar
• Fava M, Thase ME, DeBattista C, Doghramji K, Arora S, Hughes RJ. Modafinil augmentation of selective serotonin reuptake inhibitor therapy in MDD partial responders with persistent fatigue and sleepiness. Ann Clin Psychiatry 2007;19:153–9.
   PubMedGoogle Scholar
• Candy M, Jones L, Williams R, Tookman A, King M. Psychostimulants for depression. Cochrane Database Syst Rev 2008 (2): CD006722.
   PubMedGoogle Scholar
• www.clinicaltrial.gov.
   Google Scholar
• Garvey MJ, Hwang S, Teubner-Rhodes D, Zander J, Rhem C. 0Dextroamphetamine treatment of mania. J Clin Psychiatry 1987;48:412–13.
   PubMedGoogle Scholar
• Bschor T, Muller-Oerlinghausen B, Ulrich G. Decreased level of EEG-vigilance in acute mania as a possible predictor for a rapid effect of methylphenidate: A case study. Clin Electroencephalogr 2001;32:36–9.
   PubMedGoogle Scholar
• Beckmann H, Heinemann H. d-Amphetamine in manic syndrome. Drug Research 1976;26:1185–6.
   Google Scholar
• Brown WA, Mueller B. Alleviation of manic symptoms with catecholamine agonists. Am J Psychiatry 1979;136:230–1.
   PubMedGoogle Scholar
• Janowsky DS, El-Yousel MK, Davis JM, Sekerke HJ. Provocation of schizophrenic symptoms by intravenous administration of methylphenidate. Arch Gen Psychiatry 1973;28:185–91.
   PubMed Web of Science ®Google Scholar
• Schoenknecht P, Olbrich S, Sander C, Spindler P, Hegerl U. Treatment of acute mania with modafinil monotherapy. Biol Psychiatry 2010;67:e55–e57.
   PubMedGoogle Scholar
• Hegerl U, Sander C, Olbrich P, Schoenknecht P. Are psychostimulants a treatment option in mania?. Pharmacopsychiatry 2009;42:169–74.
   PubMed Web of Science ®Google Scholar